The current drug pricing market is malfunctioning, an obvious conclusion to anyone who is paying attention. But why?
Like much of the healthcare sector, the current government driven, third party payer system misaligns the interests of patients and the companies that manage patients’ drug benefits (called pharmacy benefit managers, or PBMs). These misaligned interests inflate patients’ out-of-pocket costs and often encourages the use of expensive drugs when more affordable alternatives exist.
Comments